Q-omics provides the consensus-scored CHRNG profile across patient tissues and cancer cell-line models. CHRNG expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHRNG is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, CHRNG RNA expression shows 16,817 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where CHRNG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRNG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRNG survival associations across molecular data types. CHRNG RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRNG RNA expression–survival associations across cancer types. High CHRNG expression shows unfavorable associations in KIRC, KIRP, ACC, UVM and HNSC, but favorable associations in CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHRNG RNA expression.
This table summarizes CHRNG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CHRNG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRNG shows higher tumor expression in COAD, LUSC, BLCA, STAD, LIHC and CHOL. The COAD box plot shows higher CHRNG RNA expression in tumor versus normal tissue (log2 FC = +0.149, t-test p < 0.001).
This table shows molecular features associated with CHRNG in patient tissues and cancer cell lines. In patient samples, CHRNG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRNG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
